Last reviewed · How we verify
NCT06021288: KETZEREI
Standard Dose Continuous Renal Replacement Therapy (CRRT) Versus Low-Dose CRRT ( KETZEREI )
NA trial testing Effluent dose of CRRT in Critical Illness in 165 participants. Currently enrolling.
30 April 2025
Quick facts
| Lead sponsor | Universität Münster |
|---|---|
| Phase | NA |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | triple |
| Primary purpose | supportive care |
| Enrollment | 165 |
| Start date | 2 October 2023 |
| Primary completion | 30 April 2025 |
| Estimated completion | 30 June 2025 |
| Sites | 2 locations across Germany |
Drugs / interventions tested
- Effluent dose of CRRT
Conditions studied
- Critical Illness — all drugs for Critical Illness →
- Acute Kidney Injury — all drugs for Acute Kidney Injury →
Sponsor
Universität Münster — full company profile →
Who can join
18 and older, any sex, with Critical Illness or Acute Kidney Injury. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Acute kidney injury (AKI) is a well-recognized complication in critically ill patients, which often leads to the necessity of mechanical kidney support (CRRT). In current therapeutic regimes, CRRT is used to strictly prevent azotaemia. Thus recent clinical observations, as well as data from animal testing suggest a link between controlled azotaemia and faster renal recovery in AKI patients. The aim of the study is to improve renal recovery.
Publications & conference data
6 peer-reviewed publications reference this trial (live from Europe PMC):
-
Renal replacement therapy in ICU: from conservative to restrictive strategy.
Chaïbi K, Dreyfuss D, Gaudry S. · · 2025 · cited 2× · PMID 39838403 · DOI 10.1186/s13054-025-05271-4 -
Lower versus standard dose-intensity continuous renal replacement therapy: a protocol for a systematic review and meta-analysis.
Lumlertgul N, Kusirisin P, Kung JY, Duquette D, et al · · 2026 · cited 1× · PMID 41617237 · DOI 10.1136/bmjopen-2025-112086 -
Optimizing a Dose Prescription as the First Step of Green Continuous Kidney Replacement Therapy.
Rhee H, Kim T, Jung KS, Ku EY. · · 2025 · PMID 41050122 · DOI 10.1016/j.xkme.2025.101088 -
Randomised controlled study investigating standard dose continuous renal replacement therapy (CRRT) versus low-dose CRRT in critically ill patients with acute kidney injury (AKI): study protocol for a prospective, randomised, controlled, international, multicentre trial (the 'Ket
Strauß C, Sadjadi M, von Groote T, Booke H, et al · · 2025 · PMID 40983574 · DOI 10.1136/bmjopen-2025-105459 -
Current Status of Continuous Renal Replacement Therapy in Japanese Intensive Care Units: A Multicenter Retrospective Observational Study.
Nakano H, Inokuchi R, Inoue Y, Sekino M, et al · · 2026 · PMID 40924636 · DOI 10.1159/000548371 -
Proceedings of the University of Alabama at Birmingham Continuous Renal Replacement Therapy Academy (2023-2024): Managing De-Escalation of Acute Renal Replacement Therapy and Optimizing Drug Dosing during Renal Replacement Therapy Transitions.
Beaubien-Souligny W, Thompson Bastin M, Teixeira JP, Cerda J, et al · · 2025 · PMID 40779331 · DOI 10.34067/kid.0000000951
Verify or expand the search:
- PubMed search for NCT06021288
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Critical Illness
Currently open trials in the same condition.
- NCT06189924 — Exhaled Breath Condensate Analysis in Mechanically Ventilated Patients · recruiting
- NCT07418242 — Prognostic Value of Novel Biomarkers on Adverse Renal Outcomes in High-Risk Cardiac Surgery Patients · recruiting
- NCT07101640 — PK, Safety and Preliminary Efficacy Study of Montelukast in Critically Ill Infants With Developing Bronchopulmonary Dysp · Phase 1, PHASE2 · recruiting
- NCT07177183 — Low Serum Creatinine as a Predictor of Prolonged Mechanical Ventilation and Weaning Failure · NA · recruiting
- NCT07369258 — Clinical Application of Listening to Music to Prevent Delirium in the Intensive Care Unit · NA · recruiting
Other Universität Münster trials
Trials by the same sponsor.
- NCT07197307 — Combining Loncastuximab Tesirine and Epcoritamab in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL) · Phase 2 · not yet recruiting
- NCT06912529 — Axicabtagene Ciloleucel CAR T-cells in Patients With Relapsed or Refractory Primary Mediastinal B-cell Lymphoma · Phase 2 · terminated
- NCT06665724 — Clinical Trial Evaluating Safety of 5-Aminolevulinic Acid (5-ALA) Combined With CV01 Delivery of Ultrasound for Sonodyna · Phase 1 · completed
- NCT06727851 — ESGE-Quality Improvement in Endoscopy: ERCP · enrolling by invitation
- NCT06095713 — German Observational Multicenter Study of Patients With Fabry Disease Under Enzyme Replacement Therapy With Pegunigalsid · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06021288 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Universität Münster
- Last refreshed: 27 November 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06021288.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing